Dendritic Cells Pulsed with a Tumor-specific Peptide Induce Long-lasting Immunity and Are Effective against Murine Intracerebral Melanoma

Heimberger, Amy B.; Archer, Gary E.; Crotty, Laura E.; McLendon, Roger E.; Friedman, Allan H.; Friedman, Henry S.; Bigner, Darell D.; Sampson, John H.

doi:10.1227/00006123-200201000-00024

Cited by 20 publications

(22 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mice pre-immunized with DC mixed with pep-3-KLH and then intracerebrally challenged with melanoma cells expressing EGFRvIII had an approximately 600% increase in median survival time compared with unvaccinated controls. 30 Pre-immunized mice that survived tumor challenge were reinjected 100 days later in the contralateral hemisphere and survived showing long-lasting protection, confirming the results of Moscatello and colleagues. 26 Using a bioinformatic and combinatorial peptide approach to find a peptide that could evoke superior immune response, Wu and colleagues 31 screened the EGFRvIII peptide sequence with two software programs to predict candidate epitopes restricted by the MHC class 1 subtype HLA-A0201, which is the predominant subtype in most ethnic groups.…”

Section: Preclinical Trials Studying Active Immunization With Epidermsupporting

confidence: 81%

The Epidermal Growth Factor Variant III Peptide Vaccine for Treatment of Malignant Gliomas

Mitra

Wong

2010

Neurosurgery Clinics of North America

View full text Add to dashboard Cite

Section: Preclinical Trials Studying Active Immunization With Epidermsupporting

confidence: 81%

The Epidermal Growth Factor Variant III Peptide Vaccine for Treatment of Malignant Gliomas

Mitra

Wong

2010

Neurosurgery Clinics of North America

View full text Add to dashboard Cite

“…Results of glioma DC vaccines in animal models have confirmed its safety and efficacy [19][20][21]. In several clinical trials, DC vaccines against tumor-specific antigens was shown to be significantly effective in patients with prostate cancer, malignant melanoma, renal cell carcinoma, and multiple myeloma [12,[22][23][24][25].…”

Section: Discussionmentioning

confidence: 99%

Clinical Application of a Dendritic Cell Vaccine Raised Against Heat-Shocked Glioblastoma

Jie¹,

Hua²,

Jiang³

et al. 2011

Cell Biochem Biophys

View full text Add to dashboard Cite

Establishment of a detection platform for glioblastoma-dendritic cell (DC) vaccine preparation and to determine the efficacy of the vaccine in a clinical trial. Autologous glioblastoma-DC vaccine was prepared from a glioblast specimen procured from surgical resection. The specimen was used to enrich the vaccine with peripherally blood-derived DCs after heat-shock induced, glioblastoma apoptosis. The control group received conventional treatment of surgery and radio-chemotherapy post-operation. The therapeutic group received a combination of glioblastoma-DC vaccine and conventional therapy. A comparison of the functional immune parameters, including tumor control, rate live time, Karnofsky scores, and complications occurring in each group were observed and recorded. The proportions of peripheral CD3(+), CD3(+)CD4(+), CD4(+)/CD8(+), and NK cells were significantly higher after DC vaccination than the control group (P < 0.05). Serum levels of IL-2, IL-12, and IFN-γ were significantly higher after DC vaccination than in the control group (P < 0.05). Nine months after vaccination, tumor control rate is significantly improved in the DC group compared with the control group (P < 0.05); survival rate was significantly higher in DC group than in control group (P < 0.05) and the time to relapse was significantly longer in DC group than that in control group (P < 0.05). Karnofsky scores were better in DC vaccination group 6 and 9 months post-treatment compared with the control group (P < 0.05). The combination of glioma DC vaccine and radiotherapy/chemotherapy post-operatively enhances the immune function of patients, increases the tumor control rate, prolongs the survival time and relapse duration, improves the quality of life, and therefore provides a more effective intervention of treating glioblastoma.

show abstract

“…30 In reality, however, the immune privilege of the brain is not absolute, but was originally used to describe the observation that tissue and tumor grafts survived better in the CNS than in other peripheral sites. 31 Effective anti-CNS tumor immune responses have been generated by immune-based treatments such as adoptive T-cell transfer, 32-37 glioma-associated antigen-pulsed DCs, [3][4][5]38 and cytokine-secreting gliomas or fi- The CTLs induced by the HLA-A2-Ig/pIL-13R␣2 345-354 -artificial antigen-presenting cells (aAPCs) for 28 days were tested for tetramer staining and cytotoxic activity. Tetramer-staining cells indicate the percentage of viable CD8 ϩ HLA-A2/pIL-13R␣2 345-354 -pulsed T2 cells (T2pIL-13R␣2 345-354 ), U251 (HLA-A2, IL-13␣2 ϩ ) or pHIV-pulsed T2 cells (T2pHIV).…”

Section: Discussionmentioning

confidence: 99%

Induction of Cytotoxic T-Lymphocytes Specific for Malignant Glioma by HLA Dimer-Based Artificial Antigen-Presenting Cells

Jiang

Lü

Liu

et al. 2007

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

show abstract

Dendritic Cells Pulsed with a Tumor-specific Peptide Induce Long-lasting Immunity and Are Effective against Murine Intracerebral Melanoma

Cited by 20 publications

References 23 publications

The Epidermal Growth Factor Variant III Peptide Vaccine for Treatment of Malignant Gliomas

The Epidermal Growth Factor Variant III Peptide Vaccine for Treatment of Malignant Gliomas

Clinical Application of a Dendritic Cell Vaccine Raised Against Heat-Shocked Glioblastoma

Induction of Cytotoxic T-Lymphocytes Specific for Malignant Glioma by HLA Dimer-Based Artificial Antigen-Presenting Cells

Contact Info

Product

Resources

About